Table 1.
Characteristics of XLH patients
| Study Group Characteristics | ||||
|---|---|---|---|---|
| Category | Whole population | Normal | Secondary Hyperparathyroidism | Tertiary Hyperparathyroidism |
| Sex (n=84) | Male: 25 (29.8%) | 4 (28.6%) | 17 (30.4%) | 4 (28.6%) |
| Female: 59 (70.2%) | 10 (71.4%) | 39 (69.6%) | 10 (71.4%) | |
| Race (n=84) | White: 80 (95.2%) | 13 (92.9%) | 53 (94.6%) | 14 (100%) |
| Black: 4 (4.8%) | 1 (7.1%) | 3 (5.4%) | 0 (0%) | |
| Age (n=84) | Adult (≥18): 40 (47.6%) | 6 (42.9%) | 22 (39.3%) | 12 (85.7%) |
| Child (<18): 44 (52.4%) | 8 (57.1%) | 34 (60.7%) | 2 (14.3%) | |
| First Calcium available (n=84) mg/dL | 9.42 (0.58) | 9.62 (0.40) | 9.35 (0.45) | 9.55 (1.11) |
| First PTH available (n=84) pg/mL | 99.57 (100.11) | 47.5 (10.94) | 81.52 (32.68) | 224.54 (196.65) |
| First Phosphorus available (n=84)* mg/dL | 2.41 (0.65) | 2.56 (0.80) | 2.46 (0.61) | 2.09 (0.49) |
| Nephrocalcinosis on renal ultrasound (n=69) | Never noted: 52 (75.4%) | 7 (63.6%) | 41 (85.4%) | 4 (40%) |
| Noted at least once: 17 (24.6%) | 4 (36.4%) | 7 (14.6%) | 6 (60%) | |
| eGFR at last measure (n=83) mL/min/1.73m2 | 111.39 (35.69) | 129.83 (40.68) | 116.03 (29.22) | 68.79 (25.29) |
Data are presented as n (%) or as Mean (standard deviation [SD]).
*
Some patient’s earliest accessible laboratory values occurred during therapy with calcitriol and phosphate.